Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,414.99
(
-0.69%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 155089

Tuesday, 01/08/2013 2:26:59 PM

Tuesday, January 08, 2013 2:26:59 PM

Post# of 257268

GILD assumed a lot of debt to acquire Sofosbuvir. ABBV developed in-house and has the advantage to undercut GILD on pricing to boost demand if needed.

The respective companies’ financial health doesn’t enter into this discussion at all, IMO. Both have more than ample financial resources to commercialize and price their HCV products as they see fit.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today